Tag: Galecto Inc (NASDAQ: GLTO)


Galecto Inc (NASDAQ: GLTO) GB0139 Displays Auspicious Security and Acceptability Outline with Promising Changes in Efficacy Markers in Hospitalized COVID-19 Patients

Galecto Inc (NASDAQ: GLTO) announced initial topline consequences from an investigator-initiated pilot probing Galecto’s gasped galectin-3 inhibitor (GB0139). This pilot included 41 hospitalized patients with COVID-19 contagion who did not require power-driven aeration, of which 20 were randomized to the GB0139 arm. GB0139 medicated at 10 mg two times a […]